COMP <GO>
COGT vs ABBV // PIOTROSKI F-SCORE QUALITY
Cogent Biosciences Inc. (NASDAQ) VS. AbbVie Inc. (NYSE) • 15-METRIC TALLY: COGT 4
— ABBV 10
▲ PIOTROSKI F-SCORE QUALITY LEADER: ABBV
LAST: $31.02 (-2.94%) • MKT CAP: $5.55B
piotroski-score
5/9
LAST: $294.89 (+1.41%) • MKT CAP: $513.86B
piotroski-score
7/9
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (COGT VS. ABBV)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | COGT | ABBV | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 41.00% | 70.20% | -29.20 | ABBV | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -35.00% | 29.00% | -64.00 | ABBV | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | 33.3x | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | -4.80% | 3.47% | -8.27 | ABBV | /fcf-yield <GO> |
| Operating Margin | -21.50% | 24.60% | -46.10 | ABBV | /operating-margins <GO> |
| Net Profit Margin | -21.20% | 6.90% | -28.10 | ABBV | /net-margins <GO> |
| Revenue Growth (YoY) | 22.00% | 8.60% | +13.40 | COGT | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 2.27% | -2.27 | ABBV | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 10.84 | 5.33 | +5.51 | COGT | /balance-sheet <GO> |
| Piotroski F-Score Quality ACTIVE | 5/9 | 7/9 | -2.00 | ABBV | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | 7.10% | 7.40% | -0.30 | COGT | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 47.4 | 72.8 | -25.38 | ABBV | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 1.05 | 1.15 | -0.10 | ABBV | /macro-sensitivity <GO> |
| Forward P/E Multiple | 22.0x | 113.1x | -91.10 | COGT | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $5.55B | $513.86B | -$508.31B | ABBV | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | COGT REV | ABBV REV | COGT GROSS % | ABBV GROSS % | COGT FCF | ABBV FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $0 | $61.16B | — | 70.2% | -$266.0M | $17.82B |
| FY 2024 | $0 | $56.33B | — | 70.0% | -$208.4M | $17.83B |
| FY 2023 | $0 | $54.32B | — | 44.0% | -$153.6M | $20.39B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
COGT // BETA 1.05
ABBV // BETA 1.15